Vertex Pharmaceuticals Stock Today
| VRTX Stock | USD 354.97 3.97 1.13% |
|
|
Vertex Pharmaceuticals is trading at 354.97 as of the 1st of December 2023; that is 1.13 percent up since the beginning of the trading day. The stock's open price was 351.0. Vertex Pharmaceuticals has a very small chance of experiencing financial distress in the next few years but had a somewhat weak performance during the last 90 days. Equity ratings for Vertex Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of November 2023 and ending today, the 1st of December 2023. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 24th of July 1991 | Category Healthcare | Classification Health Care |
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 257.68 M outstanding shares of which 2.51 M shares are at this time shorted by private and institutional investors with about 1.79 trading days to cover. More on Vertex Pharmaceuticals
Moving against Vertex Stock
| - | 0.69 | DHR | Danaher | Fiscal Quarter End 31st of December 2023 | PairCorr | |
| - | 0.67 | REVB | Revelation Biosciences | Fiscal Quarter End 31st of December 2023 | PairCorr | |
| - | 0.66 | NEOG | Neogen | Report 4th of January 2024 | PairCorr | |
| - | 0.61 | ARDX | Ardelyx | Fiscal Quarter End 31st of December 2023 | PairCorr | |
| - | 0.57 | MRNA | Moderna | Fiscal Quarter End 31st of December 2023 | PairCorr | |
| - | 0.55 | ABOS | Acumen Pharmaceuticals | Fiscal Quarter End 31st of December 2023 | PairCorr | |
| - | 0.52 | JNJ | Johnson Johnson | Aggressive Push | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Fiscal Quarter End 31st of December 2023
Vertex Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Vertex Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Vertex Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary, Vertex Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Vertex Pharmaceuticals' managers, analysts, and investors.
Environment Score | Governance Score | Social Score |
| Chairman | Joshua Boger | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Pharmaceutical Products (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| SEC Filings | Vertex Pharmaceuticals Security & Exchange Commission EDGAR Reports | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Pharmaceutical Products (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Excise Tax Activities | Animal TestingCatholic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Vertex Pharmaceuticals report their recommendations after researching Vertex Pharmaceuticals' financial statements, talking to executives and customers, or listening in on Vertex Pharmaceuticals' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Vertex Pharmaceuticals. The Vertex consensus assessment is calculated by taking the average forecast from all of the analysts covering Vertex Pharmaceuticals. Buy25 Opinions | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Piotroski F Score Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Vertex Pharmaceuticals based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Vertex Pharmaceuticals financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks. HealthyDetails
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Macroaxis Advice The buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Vertex Pharmaceuticals' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Vertex Pharmaceuticals' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Vertex Pharmaceuticals' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Vertex Pharmaceuticals' financial leverage. It provides some insight into what part of Vertex Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vertex Pharmaceuticals (VRTX) is traded on NASDAQ Exchange in USA. It is located in 50 Northern Avenue, Boston, MA, United States, 02210 and employs 4,800 people. Vertex Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 90.45 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Vertex Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Vertex Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Vertex Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 257.68 M outstanding shares of which 2.51 M shares are at this time shorted by private and institutional investors with about 1.79 trading days to cover.
Vertex Pharmaceuticals currently holds about 9.77 B in cash with 4.13 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 38.06.
Check Vertex Pharmaceuticals Probability Of Bankruptcy
OwnershipVertex Pharmaceuticals shows a total of two hundred fifty-seven million six hundred eighty-three thousand eight outstanding shares. The majority of Vertex Pharmaceuticals outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Vertex Pharmaceuticals to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Vertex Pharmaceuticals. Please pay attention to any change in the institutional holdings of Vertex Pharmaceuticals as this could imply that something significant has changed or about to change at the company. Please note that no matter how much assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Ownership Allocation
Check Vertex Ownership DetailsVertex Stock Price Odds Analysis
Based on a normal probability distribution, the odds of Vertex Pharmaceuticals jumping above the current price in 90 days from now is about 60.51%. The Vertex Pharmaceuticals probability density function shows the probability of Vertex Pharmaceuticals stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Vertex Pharmaceuticals has a beta of 0.5643. This entails as returns on the market go up, Vertex Pharmaceuticals average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Vertex Pharmaceuticals will be expected to be much smaller as well. Additionally, the company has an alpha of 0.0172, implying that it can generate a 0.0172 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Vertex Pharmaceuticals to move above the current price in 90 days from now is about 60.51 (This Vertex Pharmaceuticals probability density function shows the probability of Vertex Stock to fall within a particular range of prices over 90 days) .
Vertex Pharmaceuticals Historical Income Statement
Vertex Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting Vertex's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Vertex Pharmaceuticals revenue and expense. Vertex Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Vertex Pharmaceuticals' Weighted Average Shares is fairly stable as compared to the past year. . Weighted Average Shares Diluted is likely to rise to about 279.4 M in 2023, whereas Net Income to Non Controlling Interests is likely to drop (9.5 M) in 2023. View More FundamentalsVertex Stock Against Markets
Picking the right benchmark for Vertex Pharmaceuticals stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Vertex Pharmaceuticals stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Vertex Pharmaceuticals is critical whether you are bullish or bearish towards Vertex Pharmaceuticals at a given time. Please also check how Vertex Pharmaceuticals' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Vertex Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Center Now
Portfolio CenterAll portfolio management and optimization tools to improve performance of your portfolios |
| All Next | Launch Module |
Vertex Pharmaceuticals Corporate Directors
Vertex Pharmaceuticals corporate directors refer to members of a Vertex Pharmaceuticals board of directors. The board of directors generally takes responsibility for the Vertex Pharmaceuticals' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Vertex Pharmaceuticals' board members must vote for the resolution. The Vertex Pharmaceuticals board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| William Young | Independent Director | Profile | |
| Alan Garber | Independent Director | Profile | |
| Margaret McGlynn | Independent Director | Profile | |
| Sangeeta Bhatia | Director | Profile |
How to buy Vertex Stock?
Before investing in Vertex Pharmaceuticals, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Vertex Pharmaceuticals. To buy Vertex Pharmaceuticals stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Vertex Pharmaceuticals. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Vertex Pharmaceuticals stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Vertex Pharmaceuticals stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Vertex Pharmaceuticals stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Vertex Pharmaceuticals, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.
Already Invested in Vertex Pharmaceuticals?
The danger of trading Vertex Pharmaceuticals is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Vertex Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Vertex Pharmaceuticals. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Vertex Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Vertex Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vertex Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vertex Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vertex Pharmaceuticals Stock: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vertex Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Complementary Tools for Vertex Stock analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |
Is Vertex Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vertex Pharmaceuticals. If investors know Vertex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vertex Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.106 | Earnings Share 13.3 | Revenue Per Share 37.488 | Quarterly Revenue Growth 0.064 | Return On Assets 0.1434 |
The market value of Vertex Pharmaceuticals is measured differently than its book value, which is the value of Vertex that is recorded on the company's balance sheet. Investors also form their own opinion of Vertex Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vertex Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vertex Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vertex Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vertex Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vertex Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vertex Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.